Prognostic DNA methylation markers for renal cell carcinoma: a systematic review

Sophie C. Joosten; Ivette A. G. Deckers; Maureen J. Aarts; Ann Hoeben; Joep G. van Roermund; Kim M. Smits; Veerle Melotte; Manon van Engeland; Vivianne C. Tjan-Heijnen

doi:10.2217/epi-2017-0040

Prognostic DNA methylation markers for renal cell carcinoma: a systematic review

Sophie C. Joosten, Ivette A. G. Deckers, Maureen J. Aarts, Ann Hoeben, Joep G. van Roermund, Kim M. Smits, Veerle Melotte, Manon van Engeland, Vivianne C. Tjan-Heijnen^*

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Aim: Despite numerous published prognostic methylation markers for renal cell carcinoma (RCC), none of these have yet changed patient management. Our aim is to systematically review and evaluate the literature on prognostic DNA methylation markers for RCC. Materials & methods: We conducted an exhaustive search of PubMed, EMBASE and MEDLINE up to April 2017 and identified 49 publications. Studies were reviewed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, assessed for their reporting quality using the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria, and were graded to determine the level of evidence (LOE) for each biomarker. Results: We identified promoter methylation of BNC1, SCUBE3, GATA5, SFRP1, GREM1, RASSF1A, PCDH8, LAD1 and NEFH as promising prognostic markers. Extensive methodological heterogeneity across the included studies was observed, which hampers comparability and reproducibility of results, providing a possible explanation why these biomarkers do not reach the clinic. Conclusion: Potential prognostic methylation markers for RCC have been identified, but they require further validation in prospective studies to determine their true clinical value.

Original language	English
Pages (from-to)	1243-1257
Number of pages	15
Journal	Epigenomics
Volume	9
Issue number	9
DOIs	https://doi.org/10.2217/epi-2017-0040
Publication status	Published - Sept 2017

Keywords

biomarkers
DNA methylation
kidney cancer
prognosis
promoter CpG island methylation
renal cell carcinoma
survival
CPG ISLAND METHYLATION
INTEGRATED STAGING SYSTEM
TUMOR-SUPPRESSOR GENE
KIDNEY CANCER
PROMOTER METHYLATION
EPIGENETIC ALTERATIONS
POTENTIAL BIOMARKER
ADJUVANT SUNITINIB
DISEASE RECURRENCE
POOR-PROGNOSIS

Access to Document

10.2217/epi-2017-0040Licence: CC BY-NC-ND

Cite this

@article{2254856d2e0f4ddb9288485daa5aebca,

title = "Prognostic DNA methylation markers for renal cell carcinoma: a systematic review",

abstract = "Aim: Despite numerous published prognostic methylation markers for renal cell carcinoma (RCC), none of these have yet changed patient management. Our aim is to systematically review and evaluate the literature on prognostic DNA methylation markers for RCC. Materials & methods: We conducted an exhaustive search of PubMed, EMBASE and MEDLINE up to April 2017 and identified 49 publications. Studies were reviewed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, assessed for their reporting quality using the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria, and were graded to determine the level of evidence (LOE) for each biomarker. Results: We identified promoter methylation of BNC1, SCUBE3, GATA5, SFRP1, GREM1, RASSF1A, PCDH8, LAD1 and NEFH as promising prognostic markers. Extensive methodological heterogeneity across the included studies was observed, which hampers comparability and reproducibility of results, providing a possible explanation why these biomarkers do not reach the clinic. Conclusion: Potential prognostic methylation markers for RCC have been identified, but they require further validation in prospective studies to determine their true clinical value.",

keywords = "biomarkers, DNA methylation, kidney cancer, prognosis, promoter CpG island methylation, renal cell carcinoma, survival, CPG ISLAND METHYLATION, INTEGRATED STAGING SYSTEM, TUMOR-SUPPRESSOR GENE, KIDNEY CANCER, PROMOTER METHYLATION, EPIGENETIC ALTERATIONS, POTENTIAL BIOMARKER, ADJUVANT SUNITINIB, DISEASE RECURRENCE, POOR-PROGNOSIS",

author = "Joosten, {Sophie C.} and Deckers, {Ivette A. G.} and Aarts, {Maureen J.} and Ann Hoeben and {van Roermund}, {Joep G.} and Smits, {Kim M.} and Veerle Melotte and {van Engeland}, Manon and Tjan-Heijnen, {Vivianne C.}",

year = "2017",

month = sep,

doi = "10.2217/epi-2017-0040",

language = "English",

volume = "9",

pages = "1243--1257",

journal = "Epigenomics",

issn = "1750-1911",

publisher = "Future Medicine Ltd.",

number = "9",

}

TY - JOUR

T1 - Prognostic DNA methylation markers for renal cell carcinoma

T2 - a systematic review

AU - Joosten, Sophie C.

AU - Deckers, Ivette A. G.

AU - Aarts, Maureen J.

AU - Hoeben, Ann

AU - van Roermund, Joep G.

AU - Smits, Kim M.

AU - Melotte, Veerle

AU - van Engeland, Manon

AU - Tjan-Heijnen, Vivianne C.

PY - 2017/9

Y1 - 2017/9

N2 - Aim: Despite numerous published prognostic methylation markers for renal cell carcinoma (RCC), none of these have yet changed patient management. Our aim is to systematically review and evaluate the literature on prognostic DNA methylation markers for RCC. Materials & methods: We conducted an exhaustive search of PubMed, EMBASE and MEDLINE up to April 2017 and identified 49 publications. Studies were reviewed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, assessed for their reporting quality using the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria, and were graded to determine the level of evidence (LOE) for each biomarker. Results: We identified promoter methylation of BNC1, SCUBE3, GATA5, SFRP1, GREM1, RASSF1A, PCDH8, LAD1 and NEFH as promising prognostic markers. Extensive methodological heterogeneity across the included studies was observed, which hampers comparability and reproducibility of results, providing a possible explanation why these biomarkers do not reach the clinic. Conclusion: Potential prognostic methylation markers for RCC have been identified, but they require further validation in prospective studies to determine their true clinical value.

AB - Aim: Despite numerous published prognostic methylation markers for renal cell carcinoma (RCC), none of these have yet changed patient management. Our aim is to systematically review and evaluate the literature on prognostic DNA methylation markers for RCC. Materials & methods: We conducted an exhaustive search of PubMed, EMBASE and MEDLINE up to April 2017 and identified 49 publications. Studies were reviewed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, assessed for their reporting quality using the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria, and were graded to determine the level of evidence (LOE) for each biomarker. Results: We identified promoter methylation of BNC1, SCUBE3, GATA5, SFRP1, GREM1, RASSF1A, PCDH8, LAD1 and NEFH as promising prognostic markers. Extensive methodological heterogeneity across the included studies was observed, which hampers comparability and reproducibility of results, providing a possible explanation why these biomarkers do not reach the clinic. Conclusion: Potential prognostic methylation markers for RCC have been identified, but they require further validation in prospective studies to determine their true clinical value.

KW - biomarkers

KW - DNA methylation

KW - kidney cancer

KW - prognosis

KW - promoter CpG island methylation

KW - renal cell carcinoma

KW - survival

KW - CPG ISLAND METHYLATION

KW - INTEGRATED STAGING SYSTEM

KW - TUMOR-SUPPRESSOR GENE

KW - KIDNEY CANCER

KW - PROMOTER METHYLATION

KW - EPIGENETIC ALTERATIONS

KW - POTENTIAL BIOMARKER

KW - ADJUVANT SUNITINIB

KW - DISEASE RECURRENCE

KW - POOR-PROGNOSIS

U2 - 10.2217/epi-2017-0040

DO - 10.2217/epi-2017-0040

M3 - (Systematic) Review article

C2 - 28803494

SN - 1750-1911

VL - 9

SP - 1243

EP - 1257

JO - Epigenomics

JF - Epigenomics

IS - 9

ER -